Third Harmonic Bio

Third Harmonic Bio

Edit info

  • Founded: 2019
  • Location: Cambridge, MA
  • Employee range: 11 - 50
  • Clinical stage: RD
  • Therapy area: Chronic urticaria
  • Drug types: DRM, IMM
  • Lead product: RHB335
  • Funding: $185M IPO Sep 2022; $105M B Feb 2022


thirdharmonicbio.com

linkedin.com

job board


Business:

Allergy & Inflammation Treatments

Drug notes:

Also RD mast cell-mediated inflammatory diseases

About:

Third Harmonic Bio is developing treatments for the development of allergic and inflammatory diseases. Inflammatory diseases collectively affect millions of people worldwide and are associated with significant morbidity and mortality. By currently focusing on the inflammatory diseases of the skin, airway and gastrointestinal tract, Third Harmonic is understanding the activators or downstream mediators of mast cells, cells that are part of the immune system and primary effectors of certain inflammatory diseases. Currently, Third Harmonic has identified KIT as a cell-surface receptor found on mast cells that can be targeted with their highly selective oral approach and is in development for patients with chronic urticaria.

Post a job


© 2025 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com